Georgiamune is a company focused on reprogramming immune responses to fight cancer and autoimmune diseases by regulating signaling pathways to restore immune homeostasis.

Georgiamune

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

Parker Institute for Cancer Immunotherapy

Mubadala Capital Ventures

Verition Fund Management

General Catalyst

Bioventures Investors

Catalio Capital Management

Alexandria Venture Investments

Lauder Partners

Georgiamune Inc.

We’re incredibly proud our CEO and Founder Samir Khleif was named a winner of the prestigious EY Entrepreneur of the Year Awards for his pioneering work and groundbreaking innovations in novel biology discoveries. Congratulations to the other finalists and winners! 
 
To view all winners and learn more about the award, visit: https://go.ey.com/4eHrqW7 #EYEntrepreneurOfTheYear #EYAwards #EYEOY #novelbiology

Big news from our team today! We're excited to announce that GIM-531 has received IND clearance from the FDA. GIM-531 is a first-in-class oral treatment that selectively targets T-regulatory cells, while sparing other immune cells like CD4 and CD8. That's in addition to GIM-122, our first-in-class, dual-functioning antibody, which is in human clinical trials. 
 
We're proud to help propel novel science, and are another step closer to reprogramming immune signaling pathways to redirect the immune system to fight cancer and autoimmune diseases. Learn more: https://lnkd.in/gjtA5pRP 
#clinicaltrials #FDAclearance #cancer #firstinclass #noveldrugs

Founder and CEO Samir Khleif sat down with RJ Lumba on the Great Entrepreneurs Podcast. Hear Dr. Khleif shed light on his background, the origin of Georgiamune and our mission to reprogram immune signaling pathways to redirect the immune system to fight diseases. 

https://lnkd.in/gu7UMzsn 
#biotech #hiring

At Georgiamune Inc., we’re reprogramming immune signaling pathways to redirect the immune system to fight diseases. We’re excited to announce the clearance of our IND for our lead compound, GIM-122, a first-in-class, dual functioning monoclonal antibody. We’re also extremely grateful to the top-tier investors who helped us raise $75M in our Series A financing round. Learn more about our mission, our science and our team at www.georgiamune.com

#immunotherapy #immunooncology #biotech

Georgiamune is honored to be included on BioSpace’s prestigious List of the Top 30 Life Sciences Trailblazers for 2024! We are looking forward to 2024 as we continue to deliver novel drugs to restore immune homeostasis to fight cancer and autoimmune diseases. 

Learn more about our mission, our science, and our team at www.georgiamune.com.

#oncology #autoimmune #lifesciences #biotech

Our CEO Samir Khleif sat down with Rebecca Torrence from Business Insider to share progress on GIM-122's clinical trial, our first-in-class pipeline, and our $75 million in Series A funding, co-led by General Catalyst and Parker Institute for Cancer Immunotherapy.

Read the full article to learn how our novel biology is pioneering breakthroughs in cancer and autoimmune drugs: https://bit.ly/3vsRZMR #novelbiology #Georgiamune

COM:GEORGIAMUNE

Georgiamune

Financials Not Available